Trial reportTransfusion2015
Transfusion-related adverse events in the Platelet Dose study.
Trial report in Transfusion, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Platelet storage duration and its clinical and transfusion outcomes: a systematic review.Critical care (London, England) · 2018Pooled it
- Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.The Cochrane database of systematic reviews · 2015Pooled it
- Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.The Cochrane database of systematic reviews · 2015Pooled it
- Patient blood management in general intensive care patients.Intensive care medicine · 2026Review
- Romiplostim N01 accelerates platelet engraftment in autologousstem cell transplantation using non-cryopreserved peripheral blood stem cells for plasma cell neoplasms.Frontiers in immunology · 2026Article
- Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease.Journal of pharmaceutical health care and sciences · 2025Article
- ABO incompatibility and component irradiation are independently associated with platelet transfusion reaction rate.Transfusion · 2025Article
- Thrombocytopenia in the intensive care unit: diagnosis and management.Annals of intensive care · 2025Review
- Article
- Blood component-associated acute transfusion reactions in pediatric patients: experience of a tertiary care hospital.Turkish journal of medical sciences · 2024Article
- Chemical and Microbiological Changes of Expired Platelet Concentrate.International journal of general medicine · 2024Article
- Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation.Blood advances · 2023Article
- Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.World journal of gastroenterology · 2022Review
- Improvement of Blood Processing and Safety by Automation and Pathogen Reduction Technology.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2021Article
- Rethinking platelet transfusion practices.Blood · 2021Article
- Platelet Transfusion-Insights from Current Practice to Future Development.Journal of clinical medicine · 2021Review
- The use of premedications for platelet transfusions in pediatric patients.Hematology. American Society of Hematology. Education Program · 2020Review
- Does ABO and RhD matching matter for platelet transfusion?Hematology. American Society of Hematology. Education Program · 2020Review
- Effect of platelet storage duration on clinical outcomes and incremental platelet change in critically ill children.Transfusion · 2020Observational
- Investigating Transfusion-related Sepsis Using Culture-Independent Metagenomic Sequencing.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHow platelet (PLT) product characteristics such as dose, source (whole blood derived [WBD] vs. apheresis), storage duration, and ABO matching status affect the risks of transfusion-related adverse events (TRAEs) is unclear. Similarly, more information is needed to define how recipient characteristics affect the frequency of TRAEs after PLT transfusion. STUDY DESIGN AND
methodsIn the multicenter Platelet Dose ("PLADO") study, pediatric and adult hematology-oncology patients with hypoproliferative thrombocytopenia were randomized to receive low-dose (LD), medium-dose (MD), or high-dose (HD) PLT prophylaxis for a pretransfusion PLT count of not more than 10 × 10(9) /L. All PLT units (apheresis or WBD) were leukoreduced. Post hoc analyses of PLADO data were performed using multipredictor models.
resultsA total of 5034 PLT transfusions to 1102 patients were analyzed. A TRAE occurred with 501 PLT transfusions (10.0%). The most common TRAEs were fever (6.6% of transfusions), allergic or hypersensitivity reactions (1.9%), and sinus tachycardia (1.8%). Patients assigned HD PLTs were more likely than LD or MD patients to experience any TRAE (odds ratio for HD vs. MD, 1.50; 95% confidence interval, 1.10-2.05; three-group comparison p = 0.02). PLT source and ABO matching status were not significantly related to overall TRAE risk. Compared to a patient's first PLT transfusion, subsequent PLT transfusions were less likely to have a TRAE reported, primarily due to a lower risk of allergic or hypersensitivity reactions.
conclusionThe most important PLT unit characteristic associated with TRAEs was PLT dose per transfusion. HD PLTs may increase the risk of TRAEs, and LD PLTs may reduce the risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.